Answers are grounded in this paper and cite their sources.
Preclinical evaluation uncovers behavioral activity of polyheteroaryl candidate AD20 in zebrafish and mice, suggesting potential as an early neuroactive lead without confirmed SERT inhibition.
Depression and stress-related disorders remain important targets for the development of new neuroactive compounds. We evaluated three imidazo[1,2-a]pyridine–[1,2,5]oxadiazolo[3,4-b]pyrazine derivatives, selected by a SERT-oriented computational screen, using chemical characterization, zebrafish embryo toxicity, larval and adult zebrafish behavioural assays, mouse behavioural HPLC, and qPCR experiments. AD19/UtIA-0167 had the highest computational consensus but showed greater embryo toxicity and no consistent advantage in adult zebrafish. AD20/UtIA-0108 showed a distinct larval locomotor profile, increased middle-zone occupancy after chronic exposure in stressed adult zebrafish, and was therefore examined in mice. Chronic AD20 increased latency to enter the dark compartment; whereas, time in the light compartment, open-field measures and forced-swim immobility were unchanged. HPLC and qPCR changes were region-specific and did not demonstrate direct SERT engagement. AD20 should therefore be regarded as an early neuroactive candidate from a SERT-oriented screen, not as a confirmed SERT inhibitor or antidepressant. Interpretation across species is limited by the duplicated zebrafish serotonin-transporter system, waterborne exposure and the limited scope of the mouse behavioural effect. Direct transporter assays, pharmacokinetic studies and independent behavioural replication are required.
No takes yet. Share an insight, caveat, or question.
Komelkova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: